Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Open access
Maron, Martin S., Masri, Ahmad, Choudhury, Lubna, Olivotto, Iacopo, Saberi, Sara, Wang, Andrew, Garcia-Pavia, Pablo, Lakdawala, Neal K., Nagueh, Sherif F., Rader, Florian, Tower-Rader, Albree, Turer, Aslan T., Coats, Caroline, Fifer, Michael A., Owens, Anjali, Solomon, Scott D., Watkins, Hugh, Barriales-Villa, Roberto, Kramer, Christopher M., Wong, Timothy C., Paige, Sharon L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Wohltman, Amy, Abraham, Theodore · 2023 · Journal of the American College of Cardiology

Abstract

BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients. OBJECTIVES: This study aims to evaluate the safety and efficacy of aficamten in patients with oHCM. METHODS: Patients with oHCM and LVOT gradients ≥30 mm Hg at rest or ≥50 mm Hg with Valsalva were randomized 2:1 to receive aficamten (n = 28) or placebo (n = 13) in 2 dose-finding cohorts. Doses were titrated based on gradients and ejection fraction (EF). Safety and changes in gradient, EF, New York Heart Association functional class, and cardiac biomarkers were assessed over a 10-week treatment period and after a 2-week washout. RESULTS: From baseline to 10 weeks, aficamten reduced gradients at rest (mean difference: -40 ± 27 mm Hg, and -43 ± 37 mm Hg in Cohorts 1 and 2, P = 0.0003 and P = 0.0004 vs placebo, respectively) and with Valsalva (-36 ± 27 mm Hg and -53 ± 44 mm Hg, P = 0.001 and <0.0001 vs placebo, respectively). There were modest reductions in EF (-6% ± 7.5% and -12% ± 5.9%, P = 0.007 and P < 0.0001 vs placebo, respectively). Symptomatic improvement in ≥1 New York Heart Association functional class was observed in 31% on placebo, and 43% and 64% on aficamten in Cohorts 1 and 2, respectively (nonsignificant). With aficamten, N-terminal pro-B-type natriuretic peptide was reduced (62% relative to placebo, P = 0.0002). There were no treatment interruptions and adverse events were similar between treatment arms. CONCLUSIONS: Aficamten resulted in substantial reductions in LVOT gradients with most patients experiencing improvement in biomarkers and symptoms. These results highlight the potential of sarcomere-targeted therapy for treatment of oHCM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2022.10.020

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 204

Metadata

Authors
Maron, M. S., Masri, A., Choudhury, L., Olivotto, I., Saberi, S., Wang, A., Garcia-Pavia, P., Lakdawala, N. K., Nagueh, S. F., Rader, F., Tower-Rader, A., Turer, A. T., Coats, C., Fifer, M. A., Owens, A., Solomon, S. D., Watkins, H., Barriales-Villa, R., Kramer, C. M., Wong, T. C., Paige, S. L., Heitner, S. B., Kupfer, S., Malik, F. I., Meng, L., Wohltman, A., & Abraham, T.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2023-01
Volume
81
Issue
1
Pages
34-45
ISSN
0735-1097 (ISSN-L)
OpenAlex
W4313429960
Cited by
204
References
3
FWCI
35.71
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1016/j.jacc.2022.10.020
The paper
Maron, M. S., Masri, A., Choudhury, L., Olivotto, I., Saberi, S., Wang, A., Garcia-Pavia, P., Lakdawala, N. K., Nagueh, S. F., Rader, F., Tower-Rader, A., Turer, A. T., Coats, C., Fifer, M. A., Owens, A., Solomon, S. D., Watkins, H., Barriales-Villa, R., Kramer, C. M., . . . Abraham, T. (2023). Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2022.10.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.